clinical trial · NCT05859698
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
SchizophreniaSchizoaffective DisorderBipolar DisorderMajor Depressive DisorderTardive DyskinesiaValbenazine
brief summary
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.
started
May 9, 2023
primary completion
Dec 27, 2024
completion
Dec 27, 2024
last updated
Jan 16, 2026
official title
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol